New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
18:21 EDTAGN, VRX, SHPGAllergan CEO seeks sizeable acquisitions, WSJ reports
Allergan (AGN) CEO David Pyott says he is looking at potential sizable acquisitions, at the behest of his shareholders, as he tries to fight off a $53B hostile bid from Valeant Pharmaceuticals (VRX), and Pershing Square's Bill Ackman, The Wall Street Journal reports. Shire (SHPG) has been an often-rumored potential target of Allergan. Reference Link
News For AGN;VRX;SHPG From The Last 14 Days
Check below for free stories on AGN;VRX;SHPG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 14, 2014
16:18 EDTSHPGShire shareholders should support latest AbbVie offer, Telegraph says
Subscribe for More Information
12:47 EDTVRX, AGNAllergan slides question Valeant growth, disclosures, says BMO Capital
Subscribe for More Information
10:00 EDTSHPGOptions with decreasing implied volatility: SHPG INFY CWH FDO IDIX FAST
09:55 EDTSHPGHigh option volume stocks: PTEN MFRM GTIV SHPG IMMR
09:16 EDTSHPGOn The Fly: Pre-market Movers
HIGHER: Citigroup (C), up 3.6% after reporting better than expected Q2 results, announcing $7B settlement with DOJ and FDIC... Apple (AAPL), up 0.7% after Barclays upgrades stock to Overweight, Morgan Stanley raises Apple estimates above consensus... Shire (SHPG), up 1.6% after receiving revised proposal from AbbVie (ABBV) of GPB 53.20 per share, which it says it would be willing to recommend to Shire shareholders. AbbVie is down 2.8% after the news... Mylan (MYL), up 4% after acquiring Abbott's (ABT) non-U.S. developed markets specialty and branded generics business in all-stock transaction valued at about $5.3B. Abbott up 1.6% after the news... Progenics (PGNX), up 13% after FDA says RELISTOR can be approved on data submitted in sNDA... Exelixis (EXEL), up 13% after announcing coBRIM Phase 3 trial met primary endpoint... URS (URS) up 8% after acquired by AECOM Technology (ACM) for $56.31 per share. AECOM shares alos up 2% after deal announcement... Whiting Petroleum (WLL), up 4.5% after agreeing to acquire Kodiak Oil & Gas (KOG) in a $6B transaction. Kodiak Oil & Gas up 3%... Kandi Technologies (KNDI), up 11% after announcing JV's sale of 4,114 EVs in Q2. LOWER: Riverbed (RVBD), down 4.5% after saying it sees its Q2 adjusted EPS at low end of 26c-28c range... Harmonic (HLIT), down 13% after reporting preliminary Q2 earnings results.. EBay (EBAY), down 0.5% after downgraded at Pacific Crest, confirming partnership plans with Sotheby's (BID).
08:13 EDTVRX, AGNAllergan reiterates belief that Valeant model unsustainable in new presentation
Subscribe for More Information
08:02 EDTAGN, VRXValeant submits HSR filing for proposed acquisition of Allergan
Subscribe for More Information
06:03 EDTSHPGStocks with implied volatility below IV index mean; BBBY SHPG
Subscribe for More Information
05:27 EDTSHPGShire receives revised proposal from AbbVie of GPB 53.20 per share
Subscribe for More Information
July 13, 2014
17:10 EDTSHPGShire said to seek bid of near 53 pounds per share from AbbVie, Reuters says
Subscribe for More Information
July 11, 2014
16:48 EDTAGN, VRXAllergan comments on Pershing Square’s definitive proxy solicitation
Allergan (AGN) provided the following comment in response to the definitive proxy solicitation filed by Pershing Square Capital Management in connection with Pershing Square’s request to call a Special Meeting of Stockholders. At the Special Meeting, if called, Allergan stockholders would be asked to remove a majority of the company’s existing directors in connection with Valeant Pharmaceuticals' (VRX) unsolicited exchange offer to acquire all outstanding common shares of Allergan for 0.83 shares of Valeant common stock and $72.00 in cash, or subject to proration, an amount of cash or a number of Valeant common shares with the implied value set forth in the exchange offer. Under the current Board’s leadership, which includes individuals with significantly more industry experience than Pershing Square’s recommended nominees, Allergan continues to execute on its plan to drive near- and long-term organic growth, enhance its growth prospects and continue generating significant value for all of Allergan’s stockholders. We believe Pershing Square’s attempt to replace a majority of the Allergan Board is a further effort to support Valeant in its bid to acquire Allergan at a grossly inadequate price that substantially undervalues the company and creates significant risks and uncertainties for Allergan stockholders. Valeant has repeatedly failed to address the serious concerns raised by Allergan and important members of the investment community about Valeant’s anemic organic growth driven by unsustainable price increases, among other fundamental business model issues. Allergan has a track record of consistently acting in the best interests of its stockholders and the Board remains confident in the company’s ability to create significantly more value than Valeant’s proposal.
16:46 EDTSHPGStocks end week lower on European, Fed concerns
Subscribe for More Information
14:13 EDTSHPGShire, AbbVie didn't commit to further talks, Dow reports
Subscribe for More Information
13:58 EDTSHPGShire confirms meeting with AbbVie representatives
Subscribe for More Information
11:54 EDTSHPG, AGNAbbVie, Shire in active takeover talks, Bloomberg reports
AbbVie (ABBV) and Shire (SHPG) are in active talks about a potential merger after AbbVie raised its takeover offer for a fourth time, Bloomberg reports, citing people with knowledge of the matter. The talks are in the early stage and may not lead to an agreement, sources told Bloomberg. Shares of Shire are up 5%, or $12.04, to $250.65 following the report.
11:34 EDTSHPGShire jumps 5% after Bloomberg report on talks with AbbVie
11:33 EDTSHPGShire, AbbVie held talks after latest raised takeover offer, Bloomberg says
Subscribe for More Information
July 10, 2014
09:40 EDTSHPGAbbVie, Shire not holding talks at this point as deadline approaches, CNBC says
AbbVie (ABBV) and Shire (SHPG) are not holding talks at this point, according to CNBC's David Faber, citing sources. Shire confirmed two days ago that it has received AbbVie's latest, raised takeover offer and that its board will meet to consider the proposal.
09:31 EDTVRXNestle acquires rights to aesthetic dermatology products in the U.S. and Canada
Subscribe for More Information
09:31 EDTVRXValeant completes filler, toxin asset sale to Galderma
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use